Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders ...

What happenedShares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Global Blood Therapeutics (GBT) reports results for the quarter ended March 2022. While this widely-known consensus ...

Trading at a P/B of 5.73x, Global Blood Therapeutics seems to be a reasonably valued stock. Despite the risk profile of the company, I feel that this can emerge as a major SCD player in future years.

Global Blood, based in South San Francisco, Calif., had expected to price its offering at $16 to $18 per share. Its stock is listed on the Nasdaq Global Market under the symbol “GBT.” Policies ...

What: Global Blood Therapeutics (GBT) is down 19% at 12:30 p.m. EST after releasing data for its sickle cell drug GBT440 at the American Society of Hematology (ASH) meeting over the weekend.